Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease, affecting an ...
Simple, reliable and scalable blood-based testing could identify patients with at-risk MASH among nearly 90 million U.S. individuals receiving medical attention due to MASLD-related risk factorsIQVIA ...
Discover six MASH companies to keep an eye on as the race to shape the next generation of liver disease therapies heats up.
LONDON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- (“Tangram”), a company committed to unlocking transformative RNAi medicines for meaningful patient impact, today announced progression of its MASH ...
Last patient completed final 72-week visit in NATiV3, with 1,009 patients enrolled in the main cohort and 410 patients in the ...
Metabolic dysfunction-associated steatohepatitis (MASH) is a “silent disease” that often has no early symptoms, yet can progress to cirrhosis or liver failure. Possible MASH symptoms include ...
NEW YORK, NEW YORK - JUNE 21: Dan Marino speaks onstage at Fanatics Fest NYC 2025 at Javits Center on June 21, 2025 in New York City. (Photo by Slaven Vlasic/Getty Images) To say that Dan Marino has ...
21m
GENFIT S.A.: GENFIT Highlights Long-Term Commercial Opportunity for its MASH Diagnostics Technology
Simple, reliable and scalable blood-based testing could identify patients with at-risk MASH among nearly 90 million U.S. individuals receiving medical attention due to MASLD-related risk factorsIQVIA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results